DUBLIN--(BUSINESS WIRE)--The "Global Drug Substance Manufacturing - Procurement Market Intelligence Report" report has been added to ResearchAndMarkets.com's offering.
The report provides up-to-date information about market shifts and potential risks, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. It focuses on the cost-saving aspects of procurement and on providing insights that can lead to optimization of category spend.
The report provides actionable insights to improve source-to-contract cycle performance in the Global Drug Substance Manufacturing Market. It helps sourcing professionals formulate better category strategies, enhance savings, understand supplier and market challenges, and implement sourcing best practices.
One of the best procurement practices for the buyers is to engage with suppliers that implement flexible production practices such as virtual engineering.
According to the report, a major growth driver of this market includes the demand for pharmaceutical drugs, which is increasing owing to the rise in aging population and chronic disease levels.
Further, the report states that a key procurement challenge faced by buyers is the difficulty in forecasting biologic drug production. The biologics drug development and approval process are long and fraught with complications, resulting in risk of inaccurately demand forecasting.
- Pfizer CentreOne
- Dr. Reddy's
Key Topics Covered
1. Category at a Glance
2. Scope of the Report
3. Market Insights
4. Supply Market Insights
5. Pricing Insights
6. Procurement Insights
7. Top Five Suppliers
For more information about this report visit https://www.researchandmarkets.com/research/pm23mn/drug_substance?w=4